135 related articles for article (PubMed ID: 23883783)
1. Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
Patel MR; Jay-Dixon J; Sadiq AA; Jacobson BA; Kratzke RA
J Thorac Oncol; 2013 Sep; 8(9):1142-7. PubMed ID: 23883783
[TBL] [Abstract][Full Text] [Related]
2.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
3. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
4. β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer.
Xu C; Jiang ZB; Shao L; Zhao ZM; Fan XX; Sui X; Yu LL; Wang XR; Zhang RN; Wang WJ; Xie YJ; Zhang YZ; Nie XW; Xie C; Huang JM; Wang J; Wang J; Leung EL; Wu QB
Pharmacol Res; 2023 May; 191():106739. PubMed ID: 36948327
[TBL] [Abstract][Full Text] [Related]
5. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Kwak EL; Sordella R; Bell DW; Godin-Heymann N; Okimoto RA; Brannigan BW; Harris PL; Driscoll DR; Fidias P; Lynch TJ; Rabindran SK; McGinnis JP; Wissner A; Sharma SV; Isselbacher KJ; Settleman J; Haber DA
Proc Natl Acad Sci U S A; 2005 May; 102(21):7665-70. PubMed ID: 15897464
[TBL] [Abstract][Full Text] [Related]
6. RNA Structural Dynamics Modulate EGFR-TKI Resistance Through Controlling YRDC Translation in NSCLC Cells.
Shi B; An K; Wang Y; Fei Y; Guo C; Cliff Zhang Q; Yang YG; Tian X; Kan Q
Genomics Proteomics Bioinformatics; 2023 Aug; 21(4):850-865. PubMed ID: 36435452
[TBL] [Abstract][Full Text] [Related]
7. A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis.
Li J; Chen P; Wu Q; Guo L; Leong KW; Chan KI; Kwok HF
Cell Mol Life Sci; 2022 Dec; 79(12):614. PubMed ID: 36456730
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.
Haque I; Kawsar HI; Motes H; Sharma M; Banerjee S; Banerjee SK; Godwin AK; Huang CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291316
[TBL] [Abstract][Full Text] [Related]
9. A Beclin 1-targeting stapled peptide synergizes with erlotinib to potently inhibit proliferation of non-small-cell lung cancer cells.
Chen J; Zhang X; Gao S; Li N; Keng V; Zhao Y
Biochem Biophys Res Commun; 2022 Dec; 636(Pt 1):125-131. PubMed ID: 36332474
[TBL] [Abstract][Full Text] [Related]
10. JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation.
Shen J; Liu G; Qi H; Xiang X; Shao J
Cell Death Dis; 2023 Oct; 14(10):657. PubMed ID: 37813845
[TBL] [Abstract][Full Text] [Related]
11. AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models.
Polonio-Alcalá E; Porta R; Ruiz-Martínez S; Vásquez-Dongo C; Relat J; Bosch-Barrera J; Ciurana J; Puig T
Biomed Pharmacother; 2022 Dec; 156():113942. PubMed ID: 36411628
[TBL] [Abstract][Full Text] [Related]
12. Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
Chen JQ; Lee JH; Herrmann MA; Park KS; Heldman MR; Goldsmith PK; Wang Y; Giaccone G
Mol Cancer Ther; 2013 Nov; 12(11):2601-13. PubMed ID: 23979919
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.
Zhang G; Fang B; Liu RZ; Lin H; Kinose F; Bai Y; Oguz U; Remily-Wood ER; Li J; Altiok S; Eschrich S; Koomen J; Haura EB
J Proteome Res; 2011 Jan; 10(1):305-19. PubMed ID: 21080693
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
15.
McMahon NP; Solanki A; Wang LG; Montaño AR; Jones JA; Samkoe KS; Tichauer KM; Gibbs SL
Theranostics; 2024; 14(7):2816-2834. PubMed ID: 38773974
[No Abstract] [Full Text] [Related]
16. Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer.
Zhang J; Zhao K; Zhou W; Kang R; Wei S; Shu Y; Yu C; Ku Y; Mao Y; Luo H; Yang J; Mei J; Pu Q; Deng S; Zha Z; Yuan G; Shen S; Chen Y; Liu L
Signal Transduct Target Ther; 2024 Mar; 9(1):65. PubMed ID: 38461173
[TBL] [Abstract][Full Text] [Related]
17. EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
Fung C; Chen X; Grandis JR; Duvvuri U
Cancer Biol Ther; 2012 Dec; 13(14):1417-24. PubMed ID: 22954701
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.
Lin Z; Li J; Zhang J; Feng W; Lu J; Ma X; Ding W; Ouyang S; Lu J; Yue P; Wan G; Liu P; Zhang X
Cancer Res; 2023 Jul; 83(13):2187-2207. PubMed ID: 37061993
[TBL] [Abstract][Full Text] [Related]
19. Role of metabolic reprogramming in drug resistance to epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu Y; Gao W; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 May; 46(5):545-551. PubMed ID: 34148892
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer.
Praveen P; Hülsmann H; Sültmann H; Kuner R; Fröhlich H
Sci Rep; 2016 Jun; 6():27514. PubMed ID: 27279498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
